Irritable bowel syndrome, functional dyspepsia, and functional abdominal pain syndrome

Adolescent Medicine Clinics

Volumn 15, Issue 1, 2004, Pages 1-15

  Hyams, Jeffrey S ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b Farmington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; BUSPIRONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CISAPRIDE; CITALOPRAM; CLONIDINE; DICYCLOVERINE; ERYTHROMYCIN; FAMOTIDINE; HYOSCYAMINE; LACTULOSE; LOPERAMIDE; MACROGOL 3350; MAGNESIUM HYDROXIDE; METOCLOPRAMIDE; MIRALAX; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PEPPERMINT OIL; PROTON PUMP INHIBITOR; RANITIDINE; SENNA EXTRACT; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; STOMACH SECRETION INHIBITOR; SUMATRIPTAN; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANAMNESIS; CONSTIPATION; CROHN DISEASE; DIETARY INTAKE; DISEASE EXACERBATION; DROWSINESS; DRUG EFFICACY; DYSPEPSIA; HUMAN; IRRITABILITY; IRRITABLE COLON; LOW DRUG DOSE; MEDICAL ASSESSMENT; ORTHOSTATIC HYPERTENSION; PSYCHOLOGICAL ASPECT; REVIEW; SEDATION; SIDE EFFECT; SOCIAL PROBLEM; SYMPTOMATOLOGY; WEIGHT GAIN; XEROSTOMIA;

ABDOMINAL PAIN; ADOLESCENT; ADOLESCENT HEALTH SERVICES; DYSPEPSIA; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME;

EID: 3142784295     PISSN: 15473368     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.admecli.2003.11.003     Document Type: Review

References (36)

1. Hyams J.S., Burke G., Davis P.M., et al. Abdominal pain and irritable bowel syndrome in adolescents: a community-based study. J Pediatr. 129:1996;220-226
2. Apley J., Naish N. Recurrent abdominal pains: a field survey of 1, 000 school children. Arch Dis Child. 33:1958;165-170
3. Drossman D.A. The functional gastrointestinal disorders and the Rome II process. Gut. 45(Suppl II):1999;1-5
4. Gershon M.D. The enteric nervous system: a second brain. Hosp Pract. 34:1999;31-52
5. Mayer E.A., Raybould H.E. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology. 99:1990;1688-1704
6. Mertz H., Naliboff B., Munakata J., et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 109:1997;40-52
7. Gershon M.D. Roles played by 5-hydroxytryptamine in the physiology of the bowel. Alim Pharmacol Ther. 13(Suppl 2):1999;15-30
8. Kim D.Y., Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol. 95:2000;2698-2709
9. Drossman D.A. Irritable bowel syndrome and sexual/physical abuse history. Eur J Gastroenterol Hepatol. 9:1997;327-330
10. Neal K.R., Hebden J., Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: a postal survey of patients. BMJ. 314:1997;779-782
11. Gwee K.A., Leong Y.L., Graham C., et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 44:1999;400-406
12. Gwee K.A., Collins S.M., Read N.W., et al. Increased rectal mucosal expression of interleukin 1 beta in recently acquired post-infectious irritable bowel syndrome. Gut. 52:2003;523-526
13. Tornbloom H., Lindberg G., Nyberg B., et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 123:2002;1972-1979
14. Spiller R.C., Jenkins D., Thornley J.P., et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 47:2000;804-811
15. Gonsalkorale W.M., Perrey C., Pravica V., et al. Inteleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut. 52:2003;91-93
16. Bueno L., Fioramonti J., Delvaux M., et al. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology. 112:1997;1714-1743
17. O'Sullivan M., Clayton N., Breslin N.P., et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Mot. 12:2000;449-457
18. Thompson W.G., Longstreth G., Drossman D.A., et al. Functional bowel disorders and functional abdominal pain. Drossman D.A. The functional gastrointestinal disorders. 2nd edition:2000;351-432 Degnon Associates, McLean (VA)
19. Van Ginkel R., Voskuijl W.P., Benninga M.A., et al. Alterations in rectal sensitivity and motility in childhood irritable bowel syndrome. Gastroenterology. 120:2001;31-38
20. Compas B.E., Thomsen A.H. Coping and responses to stress among children with recurrent abdominal pain. J Dev Behav Pediatr. 20:1999;323-324
21. Walker L.S. Pathways between recurrent abdominal pain and adult functional gastrointestinal disorders. J Dev Behav Pediatr. 20:1999;320-322
22. Silverman D.H.S., Munakata J.A., Ennes H., et al. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology. 112:1997;64-72
23. Rasquin-Weber A., Hyman P.E., Cucchiara S., et al. Childhood functional gastrointestinal disorders. Gut. 45(Suppl II):1999;60-68
24. Sanders D.S., Carter M.J., Hurlstone D.P., et al. Association of adult celiac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet. 358:2001;1504-1508
25. Camilleri M., Choi M.G. Irritable bowel syndrome. Aliment Pharmacol Ther. 11:1997;3-15
26. Clouse R.E. Psychotropic medications for the treatment of functional gastrointestinal disorders. Clin Perspect Gastroenterol. 2:1999;348-356
27. Kline R.M., Kline J.J., DiPalma J., et al. Enteric coated, pH dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 138:2001;125-128
28. Camilleri M., Northcutt A.R., Kong S., et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 355:2000;1035-1040
29. Scott L.J., Perry C.M. Tegaserod. Drugs. 58:1999;491-496
30. Hyams J.S., Davis P., Sylvester F.A., et al. Dyspepsia in children and adolescents: a prospective study. J Pediatr Gastroenterol Nutr. 30:2000;413-418
31. Kahrilas P.J., Quigley E.M., Castell D.O., et al. The effects of tegaserod (HTF 919) on esophageal acid exposure in gastroesophageal reflux disease (GERD). Aliment Pharmacol Ther. 14:2000;1503-1559
32. Samsom M., Verhagen M.A., Van Berge Henegouwen G.P., et al. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology. 116:1999;515-520
33. Tack J., Piessevaux H., Coulie B., et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 115:1998;1346-1352
34. Macarthur C., Saunders N., Feldman W., et al. Helicobacter pylori and childhood recurrent abdominal pain: a community based case-control study. BMJ. 319:1999;822-823
35. Drossman D.A. Chronic functional abdominal pain. Am J Gastroenterol. 91:1996;2270-2281
36. Mayer E.A., Gebhart G.F. Basic and clinical aspects of visceral analgesia. Gastroenterology. 107:1994;271-293